The holy grail: pan-cancer-targeting T cells

Crowther and Dolton et al. identified an unconventional human T cell clone capable of killing many different types of cancer in vitro in an HLA-independent fashion while sparing healthy cells. Using genome-wide CRISPR-Cas9 screening, the researchers showed that the T cell clone recognized the ubiquitously expressed, mostly monomorphic, MHC-I-related protein MR1 on the surface of cancer cells when MR1 was loaded with a yet unidentified cancer-specific or cancer-associated ligand. Adoptive transfer of this T cell clone into immunodeficient NSG mice with leukemia reduced tumor burden and increased survival.

IJMS, Free Full-Text

The Quest for Cancer-Detecting Blood Tests Speeds Up

Gamma/delta T cells as cellular vehicles for anti-tumor - Frontiers

Novel strategies for cancer immunotherapy: counter-immunoediting

Michael G King Jr (@MichaelGKingJr) / X

Frontiers γδ T cells as a potential therapeutic agent for

Frontiers Adoptive NK Cell Therapy - a Beacon of Hope in

ars.els-cdn.com/content/image/1-s2.0-S000629522400

Pan-cancer T cell atlas links a cellular stress response state to

Ferroptosis: a double-edged sword mediating immune tolerance of

Targeted protein degraders from an oncologist point of view: The

Frontiers Targeting KRAS mutations in pancreatic cancer

Cancer immunoediting and resistance to T cell-based immunotherapy

Cell membrane-based biomimetic technology for cancer phototherapy